Clinical Trials on Solid Malignancies in New Zealand

Total 1606 results

Inimmune Corporation
Avance Clinical Pty Ltd.

Not yet recruiting

Trial of INI-4001 in Patients With Advanced Solid Tumours

Advanced Solid Tumor

Australia
Atridia Pty Ltd.

Active, not recruiting

A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Australia
Atridia Pty Ltd.

Completed

A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors

Solid Tumors | Neoplasm

Australia
Sun Pharma Advanced Research Company Limited

Completed

Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination

Solid Tumor in Advanced Stage

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor

Solid Tumor

United States
Morphotek

Completed

A Study of of MORAb-004 in Subjects With Solid Tumors

Solid Tumor

United States
Deborah Doroshow

Recruiting

Leflunomide in Patients With PTEN-null Advanced Solid Malignancies

PTEN-null Advanced Solid Tumors

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
PharmaMar

Completed

Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors

Solid Tumors

Spain, United States
Roswell Park Cancer Institute

Recruiting

Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients

Hematopoietic and Lymphoid System Neoplasm

United States
CanBas Co. Ltd.

Completed

CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

Advanced Solid Tumors

United States
Kinex Pharmaceuticals Inc.
Atlantic Research Group

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies

Solid Tumor

United States
Elpiscience Biopharma, Ltd.

Active, not recruiting

A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumor

United States
Roswell Park Cancer Institute
Cleveland BioLabs, Inc.

Completed

Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United States
Yale University
National Cancer Institute (NCI)

Completed

Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Yale University
National Cancer Institute (NCI)

Terminated

High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Vion Pharmaceuticals

Completed

3-AP in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Waterstone Hanxbio Pty Ltd

Completed

The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies

Advanced Solid Tumor

Australia
Martin Gutierrez
Hackensack Meridian Health; Karyopharm Therapeutics Inc

Withdrawn

Selinexor Combination Ph 1 Study

Solid Tumor Malignancy

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Green Tea Extract in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center

Completed

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Incyte Corporation

Completed

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

Unresectable or Metastatic Solid Tumors

United States
Sirnaomics

Active, not recruiting

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

Solid Tumor

United States
BeiGene

Recruiting

Study of BG-C9074 as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumor

Australia
Multitude Therapeutics (Australia) Pty Ltd

Not yet recruiting

AMT-562 in Patients With Selected Advanced Solid Tumors

Advanced Solid Tumors

Australia
Eucure (Beijing) Biopharma Co., Ltd

Recruiting

A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects With Advanced Solid Tumors

Solid Tumor

Australia
Onconova Therapeutics, Inc.

Completed

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Solid Tumor

United States
SecuraBio

Terminated

A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

Hematologic Malignancies

United States
Eikon Therapeutics
Merck Sharp & Dohme LLC

Active, not recruiting

BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

Tumor, Solid

United States
National Cancer Institute (NCI)

Completed

Selumetinib in Cancers With BRAF Mutations

Adult Solid Neoplasm

United States
Roswell Park Cancer Institute
Abbott

Completed

Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Terminated

Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Irinotecan in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

SJG-136 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors

Solid Tumors

United States
NYU Langone Health

Withdrawn

Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

Cancer | Hematological Malignancy

United States
Eli Lilly and Company

Completed

A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors

Solid Tumors

United States
Bio-Thera Solutions

Terminated

Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients

Advanced Solid Tumor

Australia
Bristol-Myers Squibb

Completed

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma

B-Cell Malignancies

United States

Clinical Trials on Solid Malignancies in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations